UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038710
Receipt number R000043925
Scientific Title Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia
Date of disclosure of the study information 2019/12/16
Last modified on 2022/05/31 12:47:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia

Acronym

Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia(NHOH-RNAseq-BALL)

Scientific Title

Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia

Scientific Title:Acronym

Feasibility study of target capture RNA-sequencing for B-cell acute lymphoblastic leukemia(NHOH-RNAseq-BALL)

Region

Japan


Condition

Condition

B-cell Acute Lymphoblastic Lekaemia

Classification by specialty

Hematology and clinical oncology Pediatrics

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Construction the framework for target capture RNA-sequencing in clinical setting

Basic objectives2

Others

Basic objectives -Others

Evaluation the effectiveness and problems of target capture RNA-sequencing

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Frequency of subtype detection by target capture RNA-sequencing within 60 days

Key secondary outcomes

Frequency of subtype detection by cytogenetic testing
Evaluating the time period to returning a report
Consistency with the results of clinical examination (RT-PCR or FISH)
Consistency with the results of other methods (RNA-seq, whole genome sequencing, target capture DNA-seq, RT-PCR)
Evaluating costs of target capture RNA-seq in clinical settings
Frequency of the patients who received allogeneic transplantation
Frequency of the patients who received tyrosine kinase inhibitor


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Newly diagnosed, relapsed, or refractory patients who diagnosed as B-ALL (NOS) or B-ALL with recurrent genetic abnormalities by WHO classification 2016
(2) Patients whose written consent was obtained within a week from diagnosis
(3) Patients who agreed to submit a specimen containing more than 10% of tumor within a week from study entry

Key exclusion criteria

Inappropriate patients judged by principal investigator or co-investigator

Target sample size

115


Research contact person

Name of lead principal investigator

1st name Takahiko
Middle name
Last name Yasuda

Organization

Nagoya Medical Center

Division name

Clinical Research Center

Zip code

460-0001

Address

4-1-1 Sannomaru, Naka-ku Nagoya, Aichi 460-0001, Japan

TEL

052-951-1111

Email

takahiko.yasuda@nnh.go.jp


Public contact

Name of contact person

1st name Daiki
Middle name
Last name Hirano

Organization

Nagoya Medical Center

Division name

Hematology Department

Zip code

460-0001

Address

4-1-1 Sannomaru, Naka-ku Nagoya, Aichi 460-0001, Japan

TEL

052-951-1111

Homepage URL


Email

hirano.daiki.jq@mail.hosp.go.jp


Sponsor or person

Institute

Nagoya Medical Center

Institute

Department

Personal name



Funding Source

Organization

National Hospital Organization

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Central IRB

Address

2-5-21 Higashigaoka, Meguro-ku, Tokyo 152-8621, Japan

Tel

03-5712-5050

Email

700-kenkyu@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 07 Month 26 Day

Date of IRB

2019 Year 07 Month 26 Day

Anticipated trial start date

2019 Year 12 Month 16 Day

Last follow-up date

2023 Year 06 Month 14 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Integrated analysis of subtype, patient characteristics and clinical examination
Search for co-existing genomic alterations in specific subtypes
Identification of novel subtypes by integrating analysis of gene expression and genomic alterations
Diagnosis of Ph-like ALL by target capture RNA-sequencing


Management information

Registered date

2019 Year 11 Month 28 Day

Last modified on

2022 Year 05 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043925


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name